2023-09-012024-08-312024-08-31false13677523ORAICLE BIOSCIENCES LTD2025-02-2672200falseiso4217:GBPxbrli:pure136775232023-09-01136775232024-08-31136775232023-09-012024-08-31136775232022-09-01136775232023-08-31136775232022-09-012023-08-3113677523bus:SmallEntities2023-09-012024-08-3113677523bus:AuditExempt-NoAccountantsReport2023-09-012024-08-3113677523bus:AbridgedAccounts2023-09-012024-08-3113677523bus:PrivateLimitedCompanyLtd2023-09-012024-08-3113677523core:WithinOneYear2024-08-3113677523core:AfterOneYear2024-08-3113677523core:WithinOneYear2023-08-3113677523core:AfterOneYear2023-08-3113677523core:ShareCapital2024-08-3113677523core:SharePremium2024-08-3113677523core:RevaluationReserve2024-08-3113677523core:OtherReservesSubtotal2024-08-3113677523core:RetainedEarningsAccumulatedLosses2024-08-3113677523core:ShareCapital2023-08-3113677523core:SharePremium2023-08-3113677523core:RevaluationReserve2023-08-3113677523core:OtherReservesSubtotal2023-08-3113677523core:RetainedEarningsAccumulatedLosses2023-08-3113677523core:LandBuildings2024-08-3113677523core:PlantMachinery2024-08-3113677523core:Vehicles2024-08-3113677523core:FurnitureFittings2024-08-3113677523core:OfficeEquipment2024-08-3113677523core:NetGoodwill2024-08-3113677523core:IntangibleAssetsOtherThanGoodwill2024-08-3113677523core:ListedExchangeTraded2024-08-3113677523core:UnlistedNon-exchangeTraded2024-08-3113677523core:LandBuildings2023-08-3113677523core:PlantMachinery2023-08-3113677523core:Vehicles2023-08-3113677523core:FurnitureFittings2023-08-3113677523core:OfficeEquipment2023-08-3113677523core:NetGoodwill2023-08-3113677523core:IntangibleAssetsOtherThanGoodwill2023-08-3113677523core:ListedExchangeTraded2023-08-3113677523core:UnlistedNon-exchangeTraded2023-08-3113677523core:LandBuildings2023-09-012024-08-3113677523core:PlantMachinery2023-09-012024-08-3113677523core:Vehicles2023-09-012024-08-3113677523core:FurnitureFittings2023-09-012024-08-3113677523core:OfficeEquipment2023-09-012024-08-3113677523core:NetGoodwill2023-09-012024-08-3113677523core:IntangibleAssetsOtherThanGoodwill2023-09-012024-08-3113677523core:ListedExchangeTraded2023-09-012024-08-3113677523core:UnlistedNon-exchangeTraded2023-09-012024-08-3113677523core:MoreThanFiveYears2023-09-012024-08-3113677523core:Non-currentFinancialInstruments2024-08-3113677523core:Non-currentFinancialInstruments2023-08-3113677523dpl:CostSales2023-09-012024-08-3113677523dpl:DistributionCosts2023-09-012024-08-3113677523core:LandBuildings2023-09-012024-08-3113677523core:PlantMachinery2023-09-012024-08-3113677523core:Vehicles2023-09-012024-08-3113677523core:FurnitureFittings2023-09-012024-08-3113677523core:OfficeEquipment2023-09-012024-08-3113677523dpl:AdministrativeExpenses2023-09-012024-08-3113677523core:NetGoodwill2023-09-012024-08-3113677523core:IntangibleAssetsOtherThanGoodwill2023-09-012024-08-3113677523dpl:GroupUndertakings2023-09-012024-08-3113677523dpl:ParticipatingInterests2023-09-012024-08-3113677523dpl:GroupUndertakingscore:ListedExchangeTraded2023-09-012024-08-3113677523core:ListedExchangeTraded2023-09-012024-08-3113677523dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-09-012024-08-3113677523core:UnlistedNon-exchangeTraded2023-09-012024-08-3113677523dpl:CostSales2022-09-012023-08-3113677523dpl:DistributionCosts2022-09-012023-08-3113677523core:LandBuildings2022-09-012023-08-3113677523core:PlantMachinery2022-09-012023-08-3113677523core:Vehicles2022-09-012023-08-3113677523core:FurnitureFittings2022-09-012023-08-3113677523core:OfficeEquipment2022-09-012023-08-3113677523dpl:AdministrativeExpenses2022-09-012023-08-3113677523core:NetGoodwill2022-09-012023-08-3113677523core:IntangibleAssetsOtherThanGoodwill2022-09-012023-08-3113677523dpl:GroupUndertakings2022-09-012023-08-3113677523dpl:ParticipatingInterests2022-09-012023-08-3113677523dpl:GroupUndertakingscore:ListedExchangeTraded2022-09-012023-08-3113677523core:ListedExchangeTraded2022-09-012023-08-3113677523dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-09-012023-08-3113677523core:UnlistedNon-exchangeTraded2022-09-012023-08-3113677523core:NetGoodwill2024-08-3113677523core:IntangibleAssetsOtherThanGoodwill2024-08-3113677523core:LandBuildings2024-08-3113677523core:PlantMachinery2024-08-3113677523core:Vehicles2024-08-3113677523core:FurnitureFittings2024-08-3113677523core:OfficeEquipment2024-08-3113677523core:AfterOneYear2024-08-3113677523core:WithinOneYear2024-08-3113677523core:ListedExchangeTraded2024-08-3113677523core:UnlistedNon-exchangeTraded2024-08-3113677523core:ShareCapital2024-08-3113677523core:SharePremium2024-08-3113677523core:RevaluationReserve2024-08-3113677523core:OtherReservesSubtotal2024-08-3113677523core:RetainedEarningsAccumulatedLosses2024-08-3113677523core:NetGoodwill2023-08-3113677523core:IntangibleAssetsOtherThanGoodwill2023-08-3113677523core:LandBuildings2023-08-3113677523core:PlantMachinery2023-08-3113677523core:Vehicles2023-08-3113677523core:FurnitureFittings2023-08-3113677523core:OfficeEquipment2023-08-3113677523core:AfterOneYear2023-08-3113677523core:WithinOneYear2023-08-3113677523core:ListedExchangeTraded2023-08-3113677523core:UnlistedNon-exchangeTraded2023-08-3113677523core:ShareCapital2023-08-3113677523core:SharePremium2023-08-3113677523core:RevaluationReserve2023-08-3113677523core:OtherReservesSubtotal2023-08-3113677523core:RetainedEarningsAccumulatedLosses2023-08-3113677523core:NetGoodwill2022-09-0113677523core:IntangibleAssetsOtherThanGoodwill2022-09-0113677523core:LandBuildings2022-09-0113677523core:PlantMachinery2022-09-0113677523core:Vehicles2022-09-0113677523core:FurnitureFittings2022-09-0113677523core:OfficeEquipment2022-09-0113677523core:AfterOneYear2022-09-0113677523core:WithinOneYear2022-09-0113677523core:ListedExchangeTraded2022-09-0113677523core:UnlistedNon-exchangeTraded2022-09-0113677523core:ShareCapital2022-09-0113677523core:SharePremium2022-09-0113677523core:RevaluationReserve2022-09-0113677523core:OtherReservesSubtotal2022-09-0113677523core:RetainedEarningsAccumulatedLosses2022-09-0113677523core:AfterOneYear2023-09-012024-08-3113677523core:WithinOneYear2023-09-012024-08-3113677523core:Non-currentFinancialInstrumentscore:CostValuation2023-09-012024-08-3113677523core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-09-012024-08-3113677523core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-09-012024-08-3113677523core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-09-012024-08-3113677523core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-09-012024-08-3113677523core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-09-012024-08-3113677523core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-09-012024-08-3113677523core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-09-012024-08-3113677523core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-09-012024-08-3113677523core:Non-currentFinancialInstrumentscore:CostValuation2024-08-3113677523core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-08-3113677523core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-08-3113677523core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-08-3113677523core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-08-3113677523core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-08-3113677523core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-08-3113677523core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-08-3113677523core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-08-3113677523core:Non-currentFinancialInstrumentscore:CostValuation2023-08-3113677523core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-08-3113677523core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-08-3113677523core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-08-3113677523core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-08-3113677523core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-08-3113677523core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-08-3113677523core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-08-3113677523core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-08-3113677523bus:Director12023-09-012024-08-3113677523bus:Director22023-09-012024-08-3113677523bus:Director32023-09-012024-08-31

ORAICLE BIOSCIENCES LTD

Registered Number
13677523
(England and Wales)

Unaudited Financial Statements for the Year ended
31 August 2024

ORAICLE BIOSCIENCES LTD
Company Information
for the year from 1 September 2023 to 31 August 2024

Directors

KULKARNI, Ritwik Dilip
PATWARDHAN, Sudhanshu Ramesh
SHARAN, Rajeshwar Nath, Dr

Registered Address

C/O Xeinadin First Floor Secure House
Lulworth Close
Chandler's Ford
SO53 3TL

Registered Number

13677523 (England and Wales)
ORAICLE BIOSCIENCES LTD
Balance Sheet as at
31 August 2024

Notes

2024

2023

£

£

£

£

Current assets
Debtors343,76513,692
Cash at bank and on hand110,550378,340
154,315392,032
Creditors amounts falling due within one year4(126,740)(206,682)
Net current assets (liabilities)27,575185,350
Total assets less current liabilities27,575185,350
Net assets27,575185,350
Capital and reserves
Called up share capital1,0001,000
Profit and loss account26,575184,350
Shareholders' funds27,575185,350
The financial statements were approved and authorised for issue by the Board of Directors on 26 February 2025, and are signed on its behalf by:
PATWARDHAN, Sudhanshu Ramesh
Director
Registered Company No. 13677523
ORAICLE BIOSCIENCES LTD
Notes to the Financial Statements
for the year ended 31 August 2024

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.
Functional and presentation currency
The financial statements are presented in sterling and this is the functional currency of the company.
Revenue from rendering of services
Revenue from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.
Current taxation
Current tax is recognised in profit or loss, except for taxes related to revaluations of land and buildings which are recognised in other comprehensive income. Current tax represents the amount of tax payable (receivable) in respect of taxable profit (loss) for the current, or past, reporting periods. Current tax is measured at the amount expected to be paid (recovered) using the tax rates and laws which have been enacted, or substantively enacted, by the balance sheet date. Where payments to HM Revenue and Customs exceed liabilities owed, an asset is recognised to the extent of the amount of tax recoverable.
2.Average number of employees

20242023
Average number of employees during the year00
3.Debtors: amounts due within one year

2024

2023

££
Trade debtors / trade receivables-13,692
Other debtors43,765-
Total43,76513,692
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
4.Creditors: amounts due within one year

2024

2023

££
Amounts owed to related parties920280
Taxation and social security4,83585,470
Accrued liabilities and deferred income120,985120,932
Total126,740206,682
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
5.Related party transactions
At the year-end the company owed Director Dr Sudhanshu Patwardhan £920.